SATURDAY, OCTOBER 1, 2016

WHO endorsed treatment may result in drug-resistant Tuberculosis

The World Health Organization recently endorsed isoniazid preventive therapy for symptom-free individuals with HIV/TB co-infection, but there is resistance to do so, as some experts said IPT may cause drug-resistance in TB.

Tuberculosis can be difficult to control in individuals with HIV, as the co-infection can disintegrate the immune system of the person infected, allowing the HIV to progress to AIDS and TB to progress to an active state, Science Translational Medicine explained in its April issue.

Studies have shown that monotherapy with isoniazid can reduce this risk of progression in TB when treatment lasts for over six months. The WHO thus released a statement that IPT treatment should be spread throughout communities as a measure to protect co-infected individuals from allowing their TB to progress.

Science Translational Medicine argued that there is not a huge statistical difference in risk with IPT, and that such programs may increase drug-resistant TB. The models tested Mycobacterium tuberculosis and found that any interstrain competition promoted drug-resistant strains through the suppression of drug-sensitive infection.

Is it speculated that IPT in small-scales will be beneficial to co-infected people with HIV/TB. Further research is suggested in order to properly treat the possible occurrence of drug-resistant TB.